HTDS - Hard To Treat Diseases Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HTDS - Hard To Treat Diseases

HTDS 0.000001000

-95.0%

May 28 12:33 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ThinkingBig	5/17/2006 9:40:42 AM
	of 271

Hard To Treat Diseases, Incorporated Announces: Involvement of Dr. Leland Shapiro Wednesday May 17, 9:35 am ET DELRAY BEACH, FL--(MARKET WIRE)--May 17, 2006 -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces that Dr. Leland Shapiro will be instrumental in the process of doing a deal with a major pharmaceutical company. Dr. Shapiro has been the principal investigator for conducting the majority of experiments and lab research that culminated in HTTD's current patent applications and testing results. He has established protocols that define specific areas for additional testing that will be included in the presentations to drug companies. The process of dealing with a pharmaceutical company involves numerous steps, including a presentation that explains substantiated findings and assets and face-to-face scientific meetings. Dr. Shapiro will be actively involved in both steps. HTTD's CEO Colm J. King states, "Dr. Shapiro is an experienced medical and scientific research professional. He can discuss the testing results included in HTTD's patent applications, the detailed protocols he has established and the potential of the Company's patent rights better than any other individual. His involvement on the Company's expert team in discussing patent application discoveries and developments is a valuable asset." The Company is aggressively moving forward by positioning its assets for acquisition by a major drug company that specializes in oncology and infectious diseases. An expert team is focused on the process of presentations and negotiations for the benefit of patients and shareholders. Additional information is available on the Company's website at: www.htdsotc.com and a presentation regarding HTTD by Mr. King is available at the following link: publiccoreport.net

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next